Targeting Th17 cells with small molecules and small interference RNA

Hui Lin, Pingfang Song, Yi Zhao, Li Jia Xue, Yi Liu, Cong-Qiu Chu

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

T helper 17 (Th17) cells play a central role in inflammatory and autoimmune diseases via the production of proinflammatory cytokines interleukin- (IL-) 17, IL-17F, and IL-22. Anti-IL-17 monoclonal antibodies show potent efficacy in psoriasis but poor effect in rheumatoid arthritis (RA) and Crohn's disease. Alternative agents targeting Th17 cells may be a better way to inhibit the development and function of Th17 cells than antibodies of blocking a single effector cytokine. Retinoic acid-related orphan receptor gamma t (RORγt) which acts as the master transcription factor of Th17 differentiation has been an attractive pharmacologic target for the treatment of Th17-mediated autoimmune disease. Recent progress in technology of chemical screen and engineering nucleic acid enable two new classes of therapeutics targeting RORγt. Chemical screen technology identified several small molecule specific inhibitors of RORγt from a small molecule library. Systematic evolution of ligands by exponential enrichment (SELEX) technology enabled target specific aptamers to be isolated from a random sequence oligonucleotide library. In this review, we highlight the development and therapeutic potential of small molecules inhibiting Th17 cells by targeting RORγt and aptamer mediated CD4+ T cell specific delivery of small interference RNA against RORγt gene expression to inhibit pathogenic effector functions of Th17 lineage.

Original languageEnglish (US)
Article number290657
JournalMediators of Inflammation
Volume2015
DOIs
StatePublished - 2015

Fingerprint

Th17 Cells
RNA Interference
Interleukin-17
Technology
Autoimmune Diseases
SELEX Aptamer Technique
Chemical Engineering
Small Molecule Libraries
Cytokines
Blocking Antibodies
Tretinoin
Psoriasis
Oligonucleotides
Crohn Disease
Nucleic Acids
Rheumatoid Arthritis
Transcription Factors
Monoclonal Antibodies
T-Lymphocytes
Gene Expression

ASJC Scopus subject areas

  • Immunology
  • Cell Biology

Cite this

Lin, H., Song, P., Zhao, Y., Xue, L. J., Liu, Y., & Chu, C-Q. (2015). Targeting Th17 cells with small molecules and small interference RNA. Mediators of Inflammation, 2015, [290657]. https://doi.org/10.1155/2015/290657

Targeting Th17 cells with small molecules and small interference RNA. / Lin, Hui; Song, Pingfang; Zhao, Yi; Xue, Li Jia; Liu, Yi; Chu, Cong-Qiu.

In: Mediators of Inflammation, Vol. 2015, 290657, 2015.

Research output: Contribution to journalArticle

Lin, Hui ; Song, Pingfang ; Zhao, Yi ; Xue, Li Jia ; Liu, Yi ; Chu, Cong-Qiu. / Targeting Th17 cells with small molecules and small interference RNA. In: Mediators of Inflammation. 2015 ; Vol. 2015.
@article{8a697529edc44956bf5ae6dfdd3edb62,
title = "Targeting Th17 cells with small molecules and small interference RNA",
abstract = "T helper 17 (Th17) cells play a central role in inflammatory and autoimmune diseases via the production of proinflammatory cytokines interleukin- (IL-) 17, IL-17F, and IL-22. Anti-IL-17 monoclonal antibodies show potent efficacy in psoriasis but poor effect in rheumatoid arthritis (RA) and Crohn's disease. Alternative agents targeting Th17 cells may be a better way to inhibit the development and function of Th17 cells than antibodies of blocking a single effector cytokine. Retinoic acid-related orphan receptor gamma t (RORγt) which acts as the master transcription factor of Th17 differentiation has been an attractive pharmacologic target for the treatment of Th17-mediated autoimmune disease. Recent progress in technology of chemical screen and engineering nucleic acid enable two new classes of therapeutics targeting RORγt. Chemical screen technology identified several small molecule specific inhibitors of RORγt from a small molecule library. Systematic evolution of ligands by exponential enrichment (SELEX) technology enabled target specific aptamers to be isolated from a random sequence oligonucleotide library. In this review, we highlight the development and therapeutic potential of small molecules inhibiting Th17 cells by targeting RORγt and aptamer mediated CD4+ T cell specific delivery of small interference RNA against RORγt gene expression to inhibit pathogenic effector functions of Th17 lineage.",
author = "Hui Lin and Pingfang Song and Yi Zhao and Xue, {Li Jia} and Yi Liu and Cong-Qiu Chu",
year = "2015",
doi = "10.1155/2015/290657",
language = "English (US)",
volume = "2015",
journal = "Mediators of Inflammation",
issn = "0962-9351",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Targeting Th17 cells with small molecules and small interference RNA

AU - Lin, Hui

AU - Song, Pingfang

AU - Zhao, Yi

AU - Xue, Li Jia

AU - Liu, Yi

AU - Chu, Cong-Qiu

PY - 2015

Y1 - 2015

N2 - T helper 17 (Th17) cells play a central role in inflammatory and autoimmune diseases via the production of proinflammatory cytokines interleukin- (IL-) 17, IL-17F, and IL-22. Anti-IL-17 monoclonal antibodies show potent efficacy in psoriasis but poor effect in rheumatoid arthritis (RA) and Crohn's disease. Alternative agents targeting Th17 cells may be a better way to inhibit the development and function of Th17 cells than antibodies of blocking a single effector cytokine. Retinoic acid-related orphan receptor gamma t (RORγt) which acts as the master transcription factor of Th17 differentiation has been an attractive pharmacologic target for the treatment of Th17-mediated autoimmune disease. Recent progress in technology of chemical screen and engineering nucleic acid enable two new classes of therapeutics targeting RORγt. Chemical screen technology identified several small molecule specific inhibitors of RORγt from a small molecule library. Systematic evolution of ligands by exponential enrichment (SELEX) technology enabled target specific aptamers to be isolated from a random sequence oligonucleotide library. In this review, we highlight the development and therapeutic potential of small molecules inhibiting Th17 cells by targeting RORγt and aptamer mediated CD4+ T cell specific delivery of small interference RNA against RORγt gene expression to inhibit pathogenic effector functions of Th17 lineage.

AB - T helper 17 (Th17) cells play a central role in inflammatory and autoimmune diseases via the production of proinflammatory cytokines interleukin- (IL-) 17, IL-17F, and IL-22. Anti-IL-17 monoclonal antibodies show potent efficacy in psoriasis but poor effect in rheumatoid arthritis (RA) and Crohn's disease. Alternative agents targeting Th17 cells may be a better way to inhibit the development and function of Th17 cells than antibodies of blocking a single effector cytokine. Retinoic acid-related orphan receptor gamma t (RORγt) which acts as the master transcription factor of Th17 differentiation has been an attractive pharmacologic target for the treatment of Th17-mediated autoimmune disease. Recent progress in technology of chemical screen and engineering nucleic acid enable two new classes of therapeutics targeting RORγt. Chemical screen technology identified several small molecule specific inhibitors of RORγt from a small molecule library. Systematic evolution of ligands by exponential enrichment (SELEX) technology enabled target specific aptamers to be isolated from a random sequence oligonucleotide library. In this review, we highlight the development and therapeutic potential of small molecules inhibiting Th17 cells by targeting RORγt and aptamer mediated CD4+ T cell specific delivery of small interference RNA against RORγt gene expression to inhibit pathogenic effector functions of Th17 lineage.

UR - http://www.scopus.com/inward/record.url?scp=84953775017&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84953775017&partnerID=8YFLogxK

U2 - 10.1155/2015/290657

DO - 10.1155/2015/290657

M3 - Article

C2 - 26792955

AN - SCOPUS:84953775017

VL - 2015

JO - Mediators of Inflammation

JF - Mediators of Inflammation

SN - 0962-9351

M1 - 290657

ER -